Home › Trials › NCT06422247
Clinical trial No longer in our active list Observational Ages 18 and up

Observational study of Japanese patients with relapsed peripheral T-cell lymphoma

Official title: Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Run by Bristol-Myers Squibb · NCT06422247 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study looks at how well current treatments work for Japanese patients with relapsed peripheral T-cell lymphoma who have already tried other therapies.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorBristol-Myers Squibb
Industry-sponsored
Locations1 site (Minato-ku, Tokyo)
Trial IDNCT06422247 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are Japanese adults aged 18 and older with a confirmed diagnosis of specific subtypes of peripheral T-cell lymphoma who have received second-line systemic therapy.

Probably not a fit

Patients who have received unapproved or off-label treatments for peripheral T-cell lymphoma may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to describe the therapeutic practices and prognosis of Japanese patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received second-line systemic therapy. It will collect data on treatment outcomes and patient characteristics to better understand the effectiveness of current therapeutic approaches. The study is observational, meaning it will not involve any experimental interventions but will focus on existing treatment regimens and their results in a real-world setting.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into effective treatment strategies for patients with relapsed peripheral T-cell lymphoma.

How similar studies have gone: While this study is observational and focuses on a specific population, similar studies have provided important data on treatment outcomes in other regions, suggesting potential for valuable findings.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female participants with a confirmed diagnosis of the specific subtypes of peripheral T-cell lymphoma (PTCL) according to The World Health Organization (WHO) classification of lymphoid neoplasm, 4th edition defined by WHO and International Agency for Research on Cancer (IARC).
* Participates aged ≥18 years of age at diagnosis of PTCL.
* Participates who have been treated with a systemic therapy for PTCL and have initiated a systemic therapy as a second-line therapy for relapsed or refractory PTCL between April 1, 2018 and March 31, 2023.

Exclusion Criteria:

* Participates who have medical history of peripheral T-cell lymphoma (PTCL) treatment by unapproved drug in Japan as of 31 March 2024 or off-label drug for PTCL in Japan as of 31 March 2024.
* Participates who have medical history of participation to a separately defined registration study for regulatory approval in PTCL.
* Participates who have medical history of PTCL treatment in a separately defined clinical study with intervention by on-label regimen for PTCL.
* Participates judged to be inappropriate for enrollment in this study by the site investigator.

Where it's running

  • Mebix, Inc
    Minato-ku, Tokyo, Japan     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Peripheral T Cell Lymphoma 36Bristol-Myers Squibb 102
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.